Inovio Pharmaceuticals Inc (INO) reported quarterly earnings results on Monday, Aug-8-2016. The company reported $-0.26 earnings per share for the quarter, missing the analyst consensus estimate by $-0.05. Analysts had a consensus of $-0.21. The company posted revenue of $6.20 million in the period, compared to analysts expectations of $4.95 million. The company’s revenue was up 17.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.09 EPS.
Inovio Pharmaceuticals Inc opened for trading at $9.75 and hit $9.89 on the upside on Friday, eventually ending the session at $9.85, with a gain of 2.18% or 0.21 points. The heightened volatility saw the trading volume jump to 15,50,156 shares. Company has a market cap of $720 M.
In a different news, on Jun 29, 2016, Morton Collins (director) purchased 10,000 shares at $9.13 per share price. According to the SEC, on May 18, 2016, Simon X Benito (director) sold 6,250 shares at $10.37 per share price. On Sep 30, 2015, Niranjan Sardesai (COO) purchased 4,000 shares at $5.50 per share price, according to the Form-4 filing with the securities and exchange commission.
Inovio Pharmaceuticals Inc. (Inovio) is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. As of December 31 2014 Inovio had completed clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers prostate cancer breast/lung/pancreatic cancer hepatitis C virus (HCV) hepatitis B virus (HBV) HIV influenza and Ebola. With its immunotherapy platform consisting of SynCon products as well as its CELLECTRA electroporation delivery technology Inovio has developed a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovio’s immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.